Axonis Secures $115 Million to Develop Novel Treatment for Drug-Resistant Pain and Epilepsy

Funding:
Axonis Therapeutics has raised $115 million in series A funding to develop its lead CNS disorder candidate, aiming to address drug-resistant pain and epilepsy.

Mechanism of Action:
The company's oral small molecule, AXN-027, works by potentiating the function of KCC2, which helps balance chloride levels in CNS neurons, enhancing their response to natural GABA-related inhibition.

Objective:
The goal is to fill the gap in treatment options for drug-resistant pain and epilepsy by leveraging this novel mechanism of action.

Development Stage:
The funding will support the advancement of AXN-027 into clinical trials, marking a significant step in addressing unmet needs in CNS disorder treatment.